Trogenix is a biotechnology company focused on creating “one-and-done” treatments for aggressive solid tumours through its Odysseus platform. The platform combines genomics, oncology, immunotherapy and gene therapy, using AAV vectors to deliver proprietary Synthetic Super-Enhancers (SSEs) directly into tumour cells while evading immune detection. These SSEs precisely regulate gene expression to expose cancer cells to the immune system and trigger tumour cell death. If residual tumour cells persist, the approach acts as a ‘Trojan horse’ to counter recurrence. Founded by life-science investor 4BIO, the company aims to advance a pipeline of potentially curative therapies toward clinical trials. Trogenix is led by CEO Ken Macnamara and is headquartered in Edinburgh, Scotland. The new capital positions the company to accelerate pre-clinical research and move multiple candidates into the clinic.

Total raised

$94M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2025